Clinical Data announced this week that its PGxHealth division is adding genetic testing for hypertrophic cardiomyopathy. The test will be added to Clinical Data's Familion family of genetic tests for cardiac syndromes.
The company described its Familion technology as “a set of highly complex genetic tests that reveal mutations associated with inherited and potentially lethal cardiac syndromes.” Other than hypertrophic cardiomyopathy, Familion assay also test for long QT syndrome, Brugada syndrome, and catecholaminergic polymorhpic ventricular tachycardia.
“Testing of family members of affected individuals is also available and important to better understand the potential for their exposure to risk from these syndromes,” the company said in a statement.
Clinical Data claims that only its Familion HCM test includes analysis of the gene troponin-C, “making it the most complete panel of cardiac sarcomere genes available.”
HCM affects approximately 1 in 500 individuals in the US, and is the most common cause of sudden cardiac death in people younger than 30. The American College of Cardiology, American Heart Association, and the European Society of Cardiology recommendgenetic testing for potential carriers of HCM.